A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer

BACKGROUND: Docetaxel is the standard first-line agent for the treatment of androgen-independent prostate cancer (AIPC). The combination of docetaxel with molecularly targeted therapies may offer the potential to increase the efficacy and decrease the toxicity of cytotoxic chemotherapy for prostate...

Descripción completa

Detalles Bibliográficos
Autores principales: Gross, Mitchell, Higano, Celestia, Pantuck, Allan, Castellanos, Olga, Green, Erica, Nguyen, Koo, Agus, David B
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1941739/
https://www.ncbi.nlm.nih.gov/pubmed/17662137
http://dx.doi.org/10.1186/1471-2407-7-142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1941739/
https://www.ncbi.nlm.nih.gov/pubmed/17662137
http://dx.doi.org/10.1186/1471-2407-7-142

Ejemplares similares